LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Article ; Online: Increasing influenza vaccination coverage in healthcare workers: analysis of an intensified on-site vaccination campaign during the COVID-19 pandemic.

Schumacher, Sofie / Salmanton-García, Jon / Liekweg, Andrea / Rolfes, Muriel / Seidel, Danila / Mellinghoff, Sibylle C / Cornely, Oliver A

Infection

2023 Volume 51, Issue 5, Page(s) 1417–1429

Abstract: ... in 2020/21.: Methods: Building on findings from our previously published review Schumacher et al ...

Abstract	Purpose: Influenza infections have substantial impact on healthcare institutions. While vaccination is the most effective preventive measure against influenza infection, vaccination coverage in healthcare workers is low. The study investigates the impact of an intensified influenza vaccination campaign in a maximum-care hospital on influenza vaccination coverage in healthcare workers during the COVID-19 pandemic in 2020/21. Methods: Building on findings from our previously published review Schumacher et al. (Infection 49(3): 387, 2021), an intensified influenza vaccination campaign comprising a mobile vaccination team providing on-site vaccination and vaccination at a recurring central vaccination site in addition to promotional measures was performed and analysed regarding vaccination coverage. A survey querying vaccination motivation was performed. Campaign strategies and vaccination coverage of influenza seasons between 2017/18 and 2019/20 were analysed. Results: The influenza vaccination campaign 2020/21 led to a significant 2.4-fold increase yielding an overall vaccination coverage of 40% among healthcare workers. A significant increase in vaccination coverage was observed across all professional fields; especially among nurses, a 2.7-fold increase, reaching a vaccination coverage of 48%, was observed. The COVID-19 pandemic positively influenced vaccination decision in 72% of first time ever or first time in over ten years influenza vaccinees. Vaccination coverage during prior vaccination campaigns focusing on educational measures did not exceed 17%. Conclusion: A mobile vaccination team providing on-site vaccination and vaccinations at a central vaccination site in addition to promotional measures can be implemented to increase influenza vaccination coverage in healthcare workers. Our concept can inform influenza and other vaccination campaigns for healthcare workers.
MeSH term(s)	Humans ; Vaccination Coverage ; Influenza, Human/epidemiology ; Influenza, Human/prevention & control ; Pandemics/prevention & control ; COVID-19/epidemiology ; COVID-19/prevention & control ; Vaccination ; Health Personnel ; Immunization Programs ; Influenza Vaccines
Chemical Substances	Influenza Vaccines
Language	English
Publishing date	2023-02-28
Publishing country	Germany
Document type	Journal Article
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/s15010-023-02007-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Increasing influenza vaccination coverage in healthcare workers: a review on campaign strategies and their effect.

Schumacher, Sofie / Salmanton-García, Jon / Cornely, Oliver A / Mellinghoff, Sibylle C

Infection

2020 Volume 49, Issue 3, Page(s) 387–399

Abstract: Purpose: Increasing influenza vaccination coverage in healthcare workers is a challenge. Especially during the ongoing COVID-19 pandemic, high vaccination coverage should be attained. This review analyzed strategies to increase influenza vaccination ... ...

Abstract	Purpose: Increasing influenza vaccination coverage in healthcare workers is a challenge. Especially during the ongoing COVID-19 pandemic, high vaccination coverage should be attained. This review analyzed strategies to increase influenza vaccination coverage in healthcare workers. Methods: A literature search using PubMed was conducted and 32 publications on influenza vaccination campaigns for healthcare workers were reviewed for key interventions and resulting vaccination coverage. Results: Among key interventions analyzed, mandatory vaccination policies or multifaceted campaigns including a vaccinate-or-wear-a-mask policy as well as mandatory declination reached vaccination coverage in healthcare workers of over 90%. Although campaigns solely based on education and promotion or on-site-vaccination did not regularly exceed an absolute vaccination coverage of 40%, a substantial relative increase in vaccination coverage was reached by implementation of these strategies. Conclusion: Mandatory vaccination policies are effective measures to achieve high overall vaccination coverage. In clinics where policies are infeasible, multifaceted campaigns comprising on-site vaccination, vaccination stands and educational and promotional campaigns as well as incentives should be implemented. Lessons learned from influenza campaigns could be implemented in future SARS-CoV-2 vaccination campaigns.
MeSH term(s)	Health Personnel ; Humans ; Immunization Programs/legislation & jurisprudence ; Immunization Programs/methods ; Immunization Programs/organization & administration ; Immunization Programs/statistics & numerical data ; Influenza A virus/immunology ; Influenza Vaccines/administration & dosage ; Influenza, Human/prevention & control ; Vaccination ; Vaccination Coverage
Chemical Substances	Influenza Vaccines
Language	English
Publishing date	2020-12-07
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/s15010-020-01555-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

Details ▾

Article ; Online: Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.

Sprute, Rosanne / Schumacher, Sofie / Pauls, Martina / Pauls, Wolfgang / Cornely, Oliver A

Drugs in R&D

2021 Volume 21, Issue 4, Page(s) 371–374

Abstract: Recently, an increasing number of cases with delayed cutaneous reaction after immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. This adverse reaction, which is considered a ... ...

Abstract	Recently, an increasing number of cases with delayed cutaneous reaction after immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported. This adverse reaction, which is considered a delayed-type or T cell-mediated hypersensitivity reaction, has been described for the Moderna (mRNA-1273) and Comirnaty (Pfizer/BioNTech, BNT162b2) vaccines. We describe a delayed large local cutaneous reaction in a patient who received the viral vector vaccine Vaxzevria (ChAdOx1-S, AstraZeneca). The time course and clinical symptoms of delayed skin reaction after mRNA vaccines have a similar pattern that we recognized in our patient after Vaxzevria vaccination. This phenomenon has not been described in the Vaxzevria clinical trials and is to our knowledge the first report of this adverse reaction to a vector-based SARS-CoV-2 vaccine. With this, we hope to raise awareness about delayed injection site reactions that also occur after viral vector vaccines and to encourage additional reporting and patient education regarding the cutaneous reactions after coronavirus disease 2019 (COVID-19) vaccination.
MeSH term(s)	COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Vaccination
Chemical Substances	COVID-19 Vaccines ; BNT162 vaccine (N38TVC63NU)
Language	English
Publishing date	2021-08-05
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2020476-0
ISSN	1179-6901 ; 1174-5886
ISSN (online)	1179-6901
ISSN	1174-5886
DOI	10.1007/s40268-021-00358-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5262: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Web-based, rapid and contactless management of ambulatory patients for SARS-CoV-2-testing.

Stemler, Jannik / Cornely, Oliver A / Noack-Schönborn, Torsten / Fohrholz, Corinna / Schumacher, Sofie / Poluschkin, Leonard / Binder, Bernd / Lehmann, Clara / Langebartels, Georg

BMC infectious diseases

2021 Volume 21, Issue 1, Page(s) 535

Abstract: Background: During the SARS-CoV-2 pandemic a mass casualty incident of ambulatory patients occurred at the COVID-19 rapid response infrastructure (CRRI) facility at the University Hospital of Cologne (UHC). We report the development of a patient-centred ...

Abstract	Background: During the SARS-CoV-2 pandemic a mass casualty incident of ambulatory patients occurred at the COVID-19 rapid response infrastructure (CRRI) facility at the University Hospital of Cologne (UHC). We report the development of a patient-centred mobile-device solution to support efficient management of the facility, triage of patients and rapid delivery of test results. Methods: The UHC-Corona Web Tool (CWT) was developed as a web-based software useable on each patient's smartphone. It provides, among others, a self-reported medical history including type and duration of symptoms and potential risk contacts and links all retrieved information to the digital patient chart via a QR code. It provides scheduling of outpatient appointments and automated transmission of SARS-CoV-2 test results. Results: The UHC-CWT was launched on 9 April 2020. It was used by 28,652 patients until 31 August 2020. Of those, 15,245 (53,2%) consulted the CRRI, representing 43,1% of all CRRI patients during the observed period. There were 8304 (29,0%) specifications concerning travel history and 17,145 (59,8%) indications of ≥1 symptom of SARS-CoV-2 infection. The most frequently indicated symptoms were sore throat (60,0%), headache (50,7%), common cold (45,1%) and cough (42,6%) while 11,057 (40,2%) patients did not report any symptoms. After implementation of the UHC-CWT, the amount of patient contacts per physician rose from 38 to 98,7 per day. The personnel for communication of test results were reduced from four on seven days to one on five days. Conclusion: The UHC-CWT is an effective digital solution for management of large numbers of outpatients for SARS-CoV-2 testing.
MeSH term(s)	Ambulatory Care Facilities ; COVID-19/diagnosis ; COVID-19 Testing/methods ; Electronic Health Records ; Germany ; Hospitals, University ; Humans ; Internet ; Male ; Medical History Taking ; Pandemics ; Smartphone ; Surveys and Questionnaires ; Travel ; Triage/methods
Language	English
Publishing date	2021-06-07
Publishing country	England
Document type	Journal Article
ISSN	1471-2334
ISSN (online)	1471-2334
DOI	10.1186/s12879-021-06249-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Web-based, rapid and contactless management of ambulatory patients for SARS-CoV-2-testing

Jannik Stemler / Oliver A. Cornely / Torsten Noack-Schönborn / Corinna Fohrholz / Sofie Schumacher / Leonard Poluschkin / Bernd Binder / Clara Lehmann / Georg Langebartels

BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-

2021 Volume 9

Abstract: Abstract Background During the SARS-CoV-2 pandemic a mass casualty incident of ambulatory patients occurred at the COVID-19 rapid response infrastructure (CRRI) facility at the University Hospital of Cologne (UHC). We report the development of a patient- ... ...

Abstract	Abstract Background During the SARS-CoV-2 pandemic a mass casualty incident of ambulatory patients occurred at the COVID-19 rapid response infrastructure (CRRI) facility at the University Hospital of Cologne (UHC). We report the development of a patient-centred mobile-device solution to support efficient management of the facility, triage of patients and rapid delivery of test results. Methods The UHC-Corona Web Tool (CWT) was developed as a web-based software useable on each patient’s smartphone. It provides, among others, a self-reported medical history including type and duration of symptoms and potential risk contacts and links all retrieved information to the digital patient chart via a QR code. It provides scheduling of outpatient appointments and automated transmission of SARS-CoV-2 test results. Results The UHC-CWT was launched on 9 April 2020. It was used by 28,652 patients until 31 August 2020. Of those, 15,245 (53,2%) consulted the CRRI, representing 43,1% of all CRRI patients during the observed period. There were 8304 (29,0%) specifications concerning travel history and 17,145 (59,8%) indications of ≥1 symptom of SARS-CoV-2 infection. The most frequently indicated symptoms were sore throat (60,0%), headache (50,7%), common cold (45,1%) and cough (42,6%) while 11,057 (40,2%) patients did not report any symptoms. After implementation of the UHC-CWT, the amount of patient contacts per physician rose from 38 to 98,7 per day. The personnel for communication of test results were reduced from four on seven days to one on five days. Conclusion The UHC-CWT is an effective digital solution for management of large numbers of outpatients for SARS-CoV-2 testing.
Keywords	COVID-19 pandemic ; SARS-CoV-2 testing strategy ; Web-based patient management ; Digital medicine ; Infectious and parasitic diseases ; RC109-216
Subject code	150
Language	English
Publishing date	2021-06-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.

Tenbusch, Matthias / Schumacher, Sofie / Vogel, Emanuel / Priller, Alina / Held, Jürgen / Steininger, Philipp / Beileke, Stephanie / Irrgang, Pascal / Brockhoff, Ronja / Salmanton-García, Jon / Tinnefeld, Kathrin / Mijocevic, Hrvoje / Schober, Kilian / Bogdan, Christian / Yazici, Sarah / Knolle, Percy / Cornely, Oliver A / Überla, Klaus / Protzer, Ulrike

The Lancet. Infectious diseases

2021 Volume 21, Issue 9, Page(s) 1212–1213

MeSH term(s)	Antibodies, Neutralizing/drug effects ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; Humans ; Immunization, Secondary/methods ; Neutralization Tests ; SARS-CoV-2/immunology
Chemical Substances	Antibodies, Neutralizing ; COVID-19 Vaccines ; ChAdOx1 COVID-19 vaccine (B5S3K2V0G8) ; BNT162 vaccine (N38TVC63NU)
Language	English
Publishing date	2021-07-29
Publishing country	United States
Document type	Letter
ZDB-ID	2061641-7
ISSN	1474-4457 ; 1473-3099
ISSN (online)	1474-4457
ISSN	1473-3099
DOI	10.1016/S1473-3099(21)00420-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5743: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Mobile PCR-based surveillance for SARS-CoV-2 to reduce visiting restrictions in nursing homes during the COVID-19 pandemic: a pilot study.

Stemler, Jannik / Kramer, Theresa / Dimitriou, Vassiliki / Wieland, Ulrike / Schumacher, Sofie / Sprute, Rosanne / Oberste, Max / Wiesmüller, Gerhard / Rau, Harald / Pieper, Sally / Bethe, Ullrich / Lehmann, Clara / Hellmich, Martin / Klein, Florian / Langebartels, Georg / Cornely, Oliver A

Infection

2021 Volume 50, Issue 3, Page(s) 607–616

Abstract: Purpose: Residents in nursing homes for the elderly (NH) are at high risk for death from COVID-19. We investigated whether repeated non-mandatory RT-PCR SARS-CoV-2 surveillance of NH staff and visitors reduces COVID-19 incidence rates in NH residents ... ...

Abstract	Purpose: Residents in nursing homes for the elderly (NH) are at high risk for death from COVID-19. We investigated whether repeated non-mandatory RT-PCR SARS-CoV-2 surveillance of NH staff and visitors reduces COVID-19 incidence rates in NH residents and allows to reduce visiting restrictions. Methods: This pilot study at the beginning of the COVID-19 pandemic compared a surveillance approach of regular, twice-weekly voluntary PCR testing of health-care workers (HCW) and visitors in interventional NH (INH) with a setting without regular testing in control NH (CNH). Residents were not tested routinely within this study. Testing was performed in a mobile testing site with same-day result reporting. SARS-CoV-2 incidence among residents in both INH and CNH was the primary endpoint; secondary endpoints being SARS-CoV-2 infection among visitors and HCW in INH. Results: Two INH and two CNH participated between October and December, 2020. At INH1, 787 tests of HCW and 350 tests of visitors were performed, accounting for 18.1% (n = 1930) of visits. At INH2, 78 tests of HCW and 372 tests of visitors were done, i.e., 30.5% (n = 1220) of visits. At the two INH 23 HCW and three visitors tested positive for SARS-CoV-2. COVID-19 outbreaks occurred among residents in INH1 (identified through study testing) and in CNH1. Utilization of voluntary testing was low. Conclusion: In a real-world setting without available rapid testing, voluntary RT-PCR SARS-CoV-2 testing of HCW and visitors does not prevent COVID-19 outbreaks in NH. Complete, non-selective testing for these groups should be instituted before visiting restrictions can be reduced. Trial registration: The study has been registered at ClinicalTrials.gov with the identifier: NCT04933981.
MeSH term(s)	Aged ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Testing ; Humans ; Nursing Homes ; Pandemics/prevention & control ; Pilot Projects ; Polymerase Chain Reaction ; SARS-CoV-2
Language	English
Publishing date	2021-10-20
Publishing country	Germany
Document type	Comparative Study ; Journal Article
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/s15010-021-01716-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

Details ▾

Article ; Online: Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA

Tenbusch, Matthias / Schumacher, Sofie / Vogel, Emanuel / Priller, Alina / Held, Juergen / Steininger, Philipp / Beileke, Stephanie / Irrgang, Pascal / Brockhoff, Ronja / Salmanton-Garcia, Jon / Tinnefeld, Kathrin / Mijocevic, Hrvoje / Schober, Kilian / Bogdan, Christian / Yazici, Sarah / Knolle, Percy / Cornely, Oliver A. / Ueberla, Klaus / Protzer, Ulrike

medRxiv

Abstract: Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria®, AstraZeneca) is associated with a certain risk for vaccine-induced immune thrombotic thrombocytopenia. Therefore, several countries have recommended replacing the second ... ...

Abstract	Administration of a first dose of the COVID-19 vaccine ChAdOx1 nCoV-19 (Vaxzevria®, AstraZeneca) is associated with a certain risk for vaccine-induced immune thrombotic thrombocytopenia. Therefore, several countries have recommended replacing the second dose of ChAdOx1 nCoV-19 with an mRNA-based vaccine as a precautionary measure, although data on safety and efficacy of such heterologous prime-boost regimen are sparse. Therefore, vaccinees, who had received a heterologous vaccination using ChAdOx1 nCoV-19 as prime and BNT162b2 (Comirnaty®, BioNTech-Pfizer) mRNA as boost vaccination were offered SARS-CoV-2 antibody testing to quantify their vaccine-induced neutralizing antibody response. The results were compared to cohorts of healthcare workers or volunteers, who received homologous BNT162b2 or homologous ChAdOx1 nCoV-19 vaccination regimens, respectively. A striking increase of vaccine-induced SARS-CoV-2 neutralizing antibody activity was observed in 229 vaccinees that received a BNT162b2 boost 9 to 12 weeks after ChAdOx1 nCoV-19 prime. In our cohort comprising over 480 individuals, the heterologous vaccination scheme induced significantly higher neutralizing antibody titers than homologous ChAdOx1 nCoV-19 and even than homologous BNT162b2 vaccination. This proves that a single dose of a COVID-19 mRNA vaccine after ChAdOx1 nCoV-19 prime vaccination is sufficient to achieve high neutralizing antibody levels predicting immune protection from SARS-CoV-2 infection, and may even increase vaccine efficacy offering an alternative in a setting of vaccine shortage.
Keywords	covid19
Language	English
Publishing date	2021-07-06
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2021.07.03.21258887
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

Rohaan, Maartje W / Borch, Troels H / van den Berg, Joost H / Met, Özcan / Kessels, Rob / Geukes Foppen, Marnix H / Stoltenborg Granhøj, Joachim / Nuijen, Bastiaan / Nijenhuis, Cynthia / Jedema, Inge / van Zon, Maaike / Scheij, Saskia / Beijnen, Jos H / Hansen, Marten / Voermans, Carlijn / Noringriis, Inge M / Monberg, Tine J / Holmstroem, Rikke B / Wever, Lidwina D V /

van Dijk, Marloes / Grijpink-Ongering, Lindsay G / Valkenet, Ludy H M / Torres Acosta, Alejandro / Karger, Matthias / Borgers, Jessica S W / Ten Ham, Renske M T / Retèl, Valesca P / van Harten, Wim H / Lalezari, Ferry / van Tinteren, Harm / van der Veldt, Astrid A M / Hospers, Geke A P / Stevense-den Boer, Marion A M / Suijkerbuijk, Karijn P M / Aarts, Maureen J B / Piersma, Djura / van den Eertwegh, Alfons J M / de Groot, Jan-Willem B / Vreugdenhil, Gerard / Kapiteijn, Ellen / Boers-Sonderen, Marye J / Fiets, W Edward / van den Berkmortel, Franchette W P J / Ellebaek, Eva / Hölmich, Lisbet R / van Akkooi, Alexander C J / van Houdt, Winan J / Wouters, Michel W J M / van Thienen, Johannes V / Blank, Christian U / Meerveld-Eggink, Aafke / Klobuch, Sebastian / Wilgenhof, Sofie / Schumacher, Ton N / Donia, Marco / Svane, Inge Marie / Haanen, John B A G

The New England journal of medicine

2022 Volume 387, Issue 23, Page(s) 2113–2125

Abstract: Background: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with ...

Abstract	Background: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. Methods: In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight). Infusion of at least 5×10 Results: A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response. Median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group and 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs and in 57% of those who received ipilimumab; in the TIL group, these events were mainly chemotherapy-related myelosuppression. Conclusions: In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.).
MeSH term(s)	Humans ; Cell- and Tissue-Based Therapy ; Ipilimumab/adverse effects ; Lymphocytes, Tumor-Infiltrating ; Melanoma/drug therapy ; Immunotherapy, Adoptive
Chemical Substances	Ipilimumab
Language	English
Publishing date	2022-12-07
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMoa2210233
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk, Leonie / Slagter, Maarten / Horlings, Hugo M / Sikorska, Karolina / van de Vijver, Koen K / de Maaker, Michiel / Nederlof, Iris / Kluin, Roelof J C / Warren, Sarah / Ong, SuFey / Wiersma, Terry G / Russell, Nicola S / Lalezari, Ferry / Schouten, Philip C / Bakker, Noor A M / Ketelaars, Steven L C / Peters, Dennis / Lange, Charlotte A H / van Werkhoven, Erik /

van Tinteren, Harm / Mandjes, Ingrid A M / Kemper, Inge / Onderwater, Suzanne / Chalabi, Myriam / Wilgenhof, Sofie / Haanen, John B A G / Salgado, Roberto / de Visser, Karin E / Sonke, Gabe S / Wessels, Lodewyk F A / Linn, Sabine C / Schumacher, Ton N / Blank, Christian U / Kok, Marleen

Nature medicine

2019 Volume 25, Issue 7, Page(s) 1175

Abstract: In the version of this article originally published, there was an error in Fig. 3j. A label on the heatmap read "TGF-α signaling via NF-κB". It should have read "TNF-α signaling via NF-κB". The error has been corrected in the HTML and PDF versions of ... ...

Abstract	In the version of this article originally published, there was an error in Fig. 3j. A label on the heatmap read "TGF-α signaling via NF-κB". It should have read "TNF-α signaling via NF-κB". The error has been corrected in the HTML and PDF versions of this article.
Language	English
Publishing date	2019-06-17
Publishing country	United States
Document type	Published Erratum
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-019-0520-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito